The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review
Open accessAbstract
Spinal muscular atrophy linked to chromosome 5q (SMA) is a recessive, progressive, neuromuscular disorder caused by bi-allelic mutations in the SMN1 gene, resulting in motor neuron degeneration and variable presentation in relation to onset and severity. A prevalence of approximately 1-2 per 100,000 persons and incidence around 1 in 10,000 live births have been estimated with SMA type I accounting for around 60% of all cases. Since SMA is a relatively rare condition, studies of its prevalence and incidence are challenging. Most published studies are outdated and therefore rely on clinical rather than genetic diagnosis. Furthermore they are performed in small cohorts in small geographical regions and only study European populations. In addition, the heterogeneity of the condition can lead to delays and difficulties in diagnosing the condition, especially outside of specialist clinics, and contributes to the challenges in understanding the epidemiology of the disease. The frequency of unaffected, heterozygous carriers of the SMN1 mutations appears to be higher among Caucasian and Asian populations compared to the Black (Sub-Saharan African ancestry) population. However, carrier frequencies cannot directly be translated into incidence and prevalence, as very severe (death in utero) and very mild (symptom free in adults) phenotypes carrying bi-allelic SMN1 mutations exist, and their frequency is unknown. More robust epidemiological data on SMA covering larger populations based on accurate genetic diagnosis or newborn screening would be helpful to support planning of clinical studies, provision of care and therapies and evaluation of outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This autosomal recessive disorder results from a mutation in the survival motor neuron SMN1 gene with an incidence of approximately 1:10,000 live births, 60% of whom have SMA type 1.2,3”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990 · cited 2×
“This results in a frame-shift and production of a protein with a different C-terminal end, which is unstable and non-functional [3, 6].”
BackgroundMethodPrevalence of Muscular Dystrophies: A Systematic Literature Review
Theadom, A., Rodrigues, M., Roxburgh, R., Balalla, S., Higgins, C., Bhattacharjee, R., Jones, K., Krishnamurthi, R., & Feigin, V. (2014) · Neuroepidemiology · doi:10.1159/000369343 · Cited by 2,046
Population frequencies of inherited neuromuscular diseases—A world survey
Emery, A. E. H. (1991) · Neuromuscular Disorders · doi:10.1016/0960-8966(91)90039-u · Cited by 1,448 · cited 1×
“In 1991, Alan Emery published a review estimating the incidence for SMA type I to be around 4–6 in 100,000 (1 in 12,500–1 in 16,667) live births [49], which was based on only three studies [50–52].”
BackgroundFeldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Lunn, M. R., & Wang, C. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60921-6 · Cited by 995
Roy, N., Mahadevan, M. S., McLean, M., Shutter, G., Yaraghi, Z., Farahani, R., Baird, S., Besner-Johnston, A., Lefebvre, C., Kang, X., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90461-1 · Cited by 981 · cited 1×
“NAIP, H4F5 and GTF2H2 are thought to be a modifiers due to their proximity to the SMN1 gene and NAIP also shows homology to apoptosis inhibitory proteins [12, 14, 16].”
BackgroundSugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661 · cited 2×
“This was seen in African Americans [46, 62, 77], as well as in Black Africans [66] and would indicate a higher proportion of 2-copy (duplication) alleles, thereby suggesting a higher number of ‘2 + 0’ carriers.”
BackgroundResultZerres, K. (1995) · Archives of Neurology · doi:10.1001/archneur.1995.00540290108025 · Cited by 563
McAndrew, P. E., Parsons, D. W., Simard, L. R., Rochette, C., Ray, P. N., Mendell, J. R., Prior, T. W., & Burghes, A. H. M. (1997) · The American Journal of Human Genetics · doi:10.1086/515465 · Cited by 543
Norwood, F. L. M., Harling, C., Chinnery, P. F., Eagle, M., Bushby, K., & Straub, V. (2009) · Brain · doi:10.1093/brain/awp236 · Cited by 541 · cited 1×
“Of three studies that investigated type II and type III separately, two found a higher prevalence of type III compared to type II [24, 32].”
Background
Research works printed but not linked: 2
- SPINRAZA® (Nusinersen) Approved in the European Union as First Treatment for Spinal Muscular Atrophy [ http://media.biogen.com/press-release/investor-relations/spinraza-nusinersen-approved-european-union-first-treatment-spinal- ].
- Ignatius J, Donner M. Epidemiology of childhood disorders (in Finnish). In: H L, editor. Lihastautien Kehittyvä Tutkimus Ja Hoito. Turku: Kiasma; 1989.
Cited by
Inflammation in CNS neurodegenerative diseases
Stephenson, J., Nutma, E., van der Valk, P., & Amor, S. (2018) · Immunology · doi:10.1111/imm.12922 · Cited by 966
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“This autosomal recessive disorder results from a mutation in the survival motor neuron SMN1 gene with an incidence of approximately 1:10,000 live births, 60% of whom have SMA type 1.(2,3) The human SMN gene is an inverted duplication on chromosome 5q13.”
BackgroundCalucho, M., Bernal, S., Alías, L., March, F., Venceslá, A., Rodríguez-Álvarez, F. J., Aller, E., Fernández, R. M., Borrego, S., Millán, J. M., et al. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2018.01.003 · Cited by 497
“3% in the meta-analysis vs the 50%–60% estimated by rate [32,33]).”
Mercuri, E., Sumner, C. J., Muntoni, F., Darras, B. T., & Finkel, R. S. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00380-8 · Cited by 430
Metadata
- Authors
- Verhaart, I. E. C., Robertson, A., Wilson, I. J., Aartsma-Rus, A., Cameron, S., Jones, C. C., Cook, S. F., & Lochmüller, H.
- Affiliations
- Newcastle University (GB)
- Biogen (United States) (US)
- Corresponding author
- Lochmüller, Hanns
- ORCID
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2017-07-04
- Volume
- 12
- Issue
- 1
- Pages
- 124-124
- ISSN
- 1750-1172 (ISSN-L)
- PMC
- PMC5496354
- OpenAlex
- W2733659072
- Cited by
- 739
- References
- 117
- Citations by year
- 2026: 82 · 2025: 108 · 2024: 125 · 2023: 91 · 2022: 90 · 2021: 91 · 2020: 63 · 2019: 45 · 2018: 33 · 2017: 2
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Orphanet Journal of Rare Diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Newcastle University ePrints (Newcastle Univesity) (cc-by)
- Funders
- Biogen
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Keywords
- spinal muscular atrophy, chromosome 5q, SMN1, prevalence, incidence, carrier frequency, heterozygous carriers, SMA type I, phenotypic heterogeneity, genetic diagnosis, newborn screening
- MeSH terms
- Chromosomes, Human, Pair 5, Female, Humans, Male, Muscular Atrophy, Spinal, Incidence, Prevalence, Survival of Motor Neuron 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. https://app.cochat.ai/papers/10.1186/s13023-017-0671-8
- The paper
- Verhaart, I. E. C., Robertson, A., Wilson, I. J., Aartsma-Rus, A., Cameron, S., Jones, C. C., Cook, S. F., & Lochmüller, H. (2017). Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/s13023-017-0671-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.